Literature DB >> 12680157

Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study.

Aleck A Hercbergs1, Lav K Goyal, John H Suh, Sy Lee, Chandana A Reddy, Bruce H Cohen, Glen H Stevens, Sethu K Reddy, David M Peereboom, Paul J Elson, Manjula K Gupta, Gene H Barnett.   

Abstract

BACKGROUND: High-dose tamoxifen has had disappointing results as a palliative therapy in recurrent glioma. Insulin-like growth factor 1 (IGF-1) is a thyroid hormone modulated naturally occurring antagonist of tamoxifen-induced cytotoxicity. Thyroid function was suppressed to reduce IGF-1 levels in glioma patients and high-dose tamoxifen administered.
MATERIALS AND METHODS: Propylthiouracil was used to induce chemical hypothyroidism in 22 patients with recurrent glioma. Tamoxifen was started within one month and given in escalating doses from 40 mg twice a day up to 80 mg 3 times a day. No significant toxicity developed.
RESULTS: Eleven out of 22 patients became hypothyroid. No patients experienced symptoms of clinical hypothyroidism. Median survival was significantly longer in the hypothyroid group (10.1 months versus 3.1 months); p = 0.03. There was a significant decrease in blood levels of IGF-1 (p = 0.02). in hypothyroid patients.
CONCLUSION: Patients treated for recurrent high-grade gliomas with high-dose tamoxifen had significantly longer survival when chemical hypothyroidism was induced with propylthiouracil.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680157

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  37 in total

Review 1.  Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

Authors:  Rebecca L Brown
Journal:  Target Oncol       Date:  2011-11-19       Impact factor: 4.493

Review 2.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

3.  Management of hypothyroidism after radiotherapy for nasopharyngeal carcinoma.

Authors:  David H Garfield; Aleck Hercbergs; Paul Davis
Journal:  Med Oncol       Date:  2008-04-30       Impact factor: 3.064

Review 4.  Thyroid hormone and anti-apoptosis in tumor cells.

Authors:  Hung-Yun Lin; Gennadi V Glinsky; Shaker A Mousa; Paul J Davis
Journal:  Oncotarget       Date:  2015-06-20

Review 5.  Targeted molecular therapy of malignant gliomas.

Authors:  Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D Stiles; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

Review 6.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Authors:  Rodrigo Dienstmann; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Oncologist       Date:  2011-12-01

Review 7.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

Review 8.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

9.  Molecular components underlying nongenomic thyroid hormone signaling in embryonic zebrafish neurons.

Authors:  Marc A Yonkers; Angeles B Ribera
Journal:  Neural Dev       Date:  2009-06-08       Impact factor: 3.842

10.  Hypothyroidism enhances tumor invasiveness and metastasis development.

Authors:  Olaia Martínez-Iglesias; Susana García-Silva; Javier Regadera; Ana Aranda
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.